PLTP Genotype

PLTP (phospholipid transfer protein) is a protein in your blood that helps reshape your cholesterol-carrying particles, especially HDL. Small inherited changes in the PLTP gene can shift how much of this protein you make, how active it is, and what your HDL particles end up looking like.

This is an exploratory genetic test. It gives you a window into one of the quieter parts of your lipid biology that a standard cholesterol panel does not capture. The result is the same for life, so a single test settles a question you would otherwise never see.

What This Test Actually Reads

This test looks at specific variants in the PLTP gene. Different versions of the gene have been linked to different levels of PLTP activity in the blood. Two well-studied variants combined into a gene score have been shown to track with lower PLTP activity and lower hepatic PLTP gene expression in human studies.

Researchers have identified tagging variants in and around PLTP (including rs6065904, rs378114, rs4810479, and rs7679) that explain roughly 11 to 30 percent of the differences in PLTP activity between people in different study groups. Other variants, like one called c.-34G>C in an intron, are tied to higher HDL cholesterol and lower triglycerides. A separate variant called rs2294213 has been linked to higher HDL cholesterol in studies of people with both unusually low and unusually high HDL.

This is a Tier 3 research marker. There are no standardized clinical cutpoints for PLTP genotype, and no professional guideline currently recommends it as a screening test. Treat it as exploratory information that adds context to your lipid picture, not as a diagnosis or definitive risk score.

How PLTP Variants Shape Your HDL

HDL is often described as a single number on a lab report, but HDL is really a population of particles that vary in size and number. PLTP is one of the proteins that determines what that population looks like.

In a meta-analysis combining five cardiovascular disease case-control studies, carrying more PLTP gene score alleles tied to lower activity was linked to a higher number of HDL particles, but those particles were smaller. A large analysis using UK Biobank data found the same direction: genetically lower PLTP activity was associated with higher HDL particle concentration, smaller HDL particle size, and higher triglyceride concentration. So your PLTP genotype helps explain why two people with identical HDL cholesterol numbers can have very different HDL particle profiles underneath.

What This Means for Heart Disease Risk

The link between PLTP genotype and heart disease is real but modest, and the picture is not fully settled.

In the pooled case-control meta-analysis, each additional copy of a lower-activity PLTP allele was associated with about 6 percent lower odds of cardiovascular disease (per-allele odds ratio 0.94). People with the highest gene score had roughly 31 percent lower odds of cardiovascular disease compared with those with the lowest (odds ratio 0.69).

A much larger Mendelian randomization analysis in UK Biobank, which uses genetics to test for a causal link, found no clear association between genetically lower PLTP activity and coronary artery disease (odds ratio 0.99, with the confidence interval crossing 1). That analysis used directly measured plasma activity as the exposure proxy, while the meta-analysis used a genetic score, which may partly explain why the signals do not line up. A separate carotid artery disease study using directly measured PLTP activity found that higher measured activity was tied to lower odds of carotid disease (about 9 percent lower odds per one-unit increase in activity).

What this means for you: PLTP genotype probably nudges cardiovascular risk in a small, context-dependent way, not in the dominant way that LDL or Lp(a) do. Use this test as a layer on top of your established risk picture (cholesterol particles, blood pressure, inflammation, family history), not as a substitute for any of them.

Reconciling the Mixed Signal

It can feel contradictory that a genetic score for lower PLTP activity is linked to lower cardiovascular risk in one study but to no clear effect in another, while higher directly measured activity is linked to lower carotid disease in a third. Part of the resolution is that these studies use fundamentally different exposure measurements: a genetic proxy for lifetime activity in some studies versus a single direct measurement of plasma activity in others. PLTP also sits in the middle of HDL remodeling, where the same shift can play out differently depending on the rest of your lipid biology. PLTP genotype is best read as a phenotype indicator that helps describe your HDL particle world, not as a stand-alone risk score where lower or higher automatically equals safer.

Connections to Obesity and Diabetes

Some PLTP variants connect more to body composition than to PLTP activity itself. Intronic PLTP haplotypes have been associated with obesity-related traits, including body mass index, waist size, and fat mass, in a family-based study. They were not tied to PLTP activity in those analyses, suggesting they may flag a nearby genetic effect on body composition rather than a direct PLTP activity change.

PLTP activity itself runs higher in people with type 2 diabetes. In one observational study, people with diabetes had about 13 percent higher plasma PLTP activity than those without, and diabetes status interacted with the PLTP gene score and waist circumference, pushing activity higher still. If you already have diabetes or significant insulin resistance, your underlying PLTP biology may behave differently than your genotype alone would predict.

Selected PLTP Variants and Their Associations

Sources: Vergeer et al., Circulation 2010; Ao et al., Journal of Clinical Lipidology 2024; Engler et al., Metabolism 2008; Chen et al., Nutrition & Metabolism 2009; Aouizerat et al., Journal of Lipid Research 2006.

One-Time Result, Lifelong Use

PLTP genotype does not change. You inherited it, and your result will be the same in five or fifty years. There is no "trend" to track on this specific test, so retesting the genotype itself is not useful unless the lab flags a concern with variant call confidence and wants to confirm with a different method.

The value of this test compounds over time as you layer it on top of your other lab work. Pair the result with regular tracking of the lipid measurements that actually move: an annual lipid panel including ApoB (apolipoprotein B), a baseline Lp(a) (lipoprotein little a) at least once in your life, and periodic checks of fasting glucose, HbA1c (hemoglobin A1c, a long-term blood sugar marker), and hs-CRP (high-sensitivity C-reactive protein, a sensitive marker of inflammation). If you are using the PLTP result to think about HDL biology specifically, an NMR (nuclear magnetic resonance) lipoprotein profile that breaks HDL into particle number and size adds the most useful texture, because that is the layer PLTP genotype most directly informs.

When Results Can Be Misleading

• Variant panel coverage: the assay only checks the specific PLTP variants it is designed to detect. A result that does not flag a known risk variant does not rule out a rarer change elsewhere in the gene that the panel does not look at.
• Ancestry-specific frequencies: the clinical meaning of a PLTP variant depends partly on how common it is in your ancestral population. Variants studied mostly in European cohorts may behave differently in people of African, East Asian, or other ancestries.
• Variants of uncertain significance: PLTP is a research-grade target, and the lab may occasionally report a variant whose clinical meaning is unclear. An uncertain variant is not the same as a risk variant.
• Clinical-grade vs direct-to-consumer assays: a 23andMe-style report covering the same gene region is not interchangeable with a clinical-grade PLTP genotyping panel. Confirmation with a clinical lab is appropriate before acting on consumer-grade calls.

Decision Pathway for an Unexpected Result

If your PLTP genotype flags a variant linked to altered PLTP activity or HDL particle profile, the next step is not more PLTP testing. It is to deepen your read on the rest of your lipid picture so the genotype actually informs a decision.

• Pair with ApoB and an NMR lipoprotein profile: these capture the LDL and HDL particle numbers and sizes that PLTP biology touches, and they give you something measurable to track.
• Confirm any Lp(a) reading: Lp(a) is a stronger inherited cardiovascular risk signal than PLTP, and if you are getting genetic context anyway, you should know your Lp(a) once.
• Recheck metabolic markers more often: PLTP activity interacts with diabetes and insulin resistance, so an annual HbA1c, fasting insulin, and triglycerides are worth tracking if your PLTP result suggests altered activity.
• Consider a lipidologist or preventive cardiologist if your PLTP result lands on top of a significant family history of early heart disease, an elevated Lp(a), or an ApoB that is not responding to standard intervention. They can read these findings together.
• Talk with a genetic counselor if you are uncertain how to interpret a variant call, especially a variant of uncertain significance, or if the result is meaningful for biological relatives.

PLTP genotype on its own rarely changes a treatment decision. What it can change is how aggressively you investigate the rest of your lipid system and how closely you track the markers that do move.